H. Lundbeck A/S
HLUN-A
Κατάταξη σε μετοχές
#3054
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Τιμή μετοχής
$7.07
Τελευταίος συγχρονισμός: 2026-10-21
Κεφαλαιοποίηση
$5.91B
Αλλαγή (1 ημέρα)
-4.56%
Αλλαγή (1 έτος)
27.71%
Χώρα
DK
Εμπόριο H. Lundbeck A/S (HLUN-A)
Κατηγορία
Healthcare
Έσοδα για την H. Lundbeck A/S (HLUN-A)
Έσοδα τον Jun 2026 TTM: $4.07B
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της H. Lundbeck A/S, τα τρέχοντα έσοδα της εταιρείας (TTM) είναι $4.07B. Το 2024, η εταιρεία είχε έσοδα $3.07B αύξηση σε σχέση με τα έσοδα του έτους 2023, τα οποία ήταν $2.95B. Τα έσοδα είναι το συνολικό ποσό που παράγει μια εταιρεία από τις πωλήσεις προϊόντων ή υπηρεσιών. Σε αντίθεση με τα κέρδη, δεν αφαιρούνται έξοδα.
Ιστορικό εσόδων για την H. Lundbeck A/S από 2004 έως 2026
Έσοδα στο τέλος κάθε έτους
| Έτος | Έσοδα | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $4.07B | 6.42% |
| 2025 | $3.83B | 24.59% |
| 2024 | $3.07B | 4.13% |
| 2023 | $2.95B | 12.26% |
| 2022 | $2.63B | 5.36% |
| 2021 | $2.49B | -14.05% |
| 2020 | $2.90B | 11.33% |
| 2019 | $2.61B | -5.10% |
| 2018 | $2.75B | -1.16% |
| 2017 | $2.78B | 25.17% |
| 2016 | $2.22B | 4.34% |
| 2015 | $2.13B | -2.91% |
| 2014 | $2.19B | -22.15% |
| 2013 | $2.81B | 7.49% |
| 2012 | $2.62B | -6.10% |
| 2011 | $2.79B | 5.28% |
| 2010 | $2.65B | -0.24% |
| 2009 | $2.65B | 25.86% |
| 2008 | $2.11B | -2.36% |
| 2007 | $2.16B | 32.74% |
| 2006 | $1.63B | 13.35% |
| 2005 | $1.44B | -19.31% |
| 2004 | $1.78B | 0.00% |
Έσοδα για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Έσοδα | Διαφορά Εσόδων | Χώρα |
|---|---|---|---|
| $2.54B | -37.70% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| $830.81M | -79.59% |
US
|
|
| - | - |
IT
|
